Spotlight On... Hype around worm study on potential Alzheimer's treatment is derided; Scripps researchers develop opioid vaccine; Bioengineers create new vehicle for drug delivery; and more...

A group of scientists from the University of Cambridge, Lund University and the University of Groningen concluded that the lymphoma drug bexarotene may interrupt the first step in the process that leads to Alzheimer's. The conclusion was reached after studying the drug on worm models for the disease. And the resulting headlines in U.K. newspapers about a potential cure for Alzheimer's led to considerable hooting on Twitter, where it was called out as another example of hyping preclinical studies. Release

> Investigators at Scripps have been at work on a new vaccine that prevents the synthetic opioid fentanyl from reaching the brain, an approach that may also be applied to designer opioids. Release

> Bioengineers at the University of Washington developed a new vehicle to carry biologics into the spinal cord. Release

> MD Anderson is highlighting new clinical work on ONC201, an experimental cancer drug from Oncoceutics. Release

Suggested Articles

UPenn scientists found blocking the Wnt/beta-catenin pathway in endothelial cells made chemotherapy more effective in mouse models of glioblastoma.

Astellas’ Xospata and Novartis’ Rydapt may help treat lung cancer that has grown resistant to EGFR inhibitors, researchers discovered.

Dutch scientists used stem cells from CF patients to demonstrate a technique that corrects a mutation in the gene CFTR without having to cut DNA.